USFDA lifts import alert on Aurobindo Pharma’s unit

The US Food and Drug Administration (USFDA) has lifted an import alert on one of Aurobindo Pharma’s units here. “The USFDA, in a Web site update, has lifted the import alert for non-sterile products manufactured in Auro Pharma’s Unit-VI cephalosporin facility based in Hyderabad,” the company informed the Bombay Stock Exchange on Thursday. The removal of the alert will help the Hyderabad-based company to resume the exports of nine products to the US market. Exports of these items were stopped after the alert on the facility imposed in February 2011. Prior to the alert, the Unit had registered annual sales of $33 million. Aurobindo Pharma’s scrip gained 11.67 per cent on the BSE on Thursday to end at Rs 145.90.